

Corresponding Author:

Date:

Martina Brueckner
September 6th, 2017

Life Sciences Reporting Summary

Nature Research wishes to improve the reproducibility of the work we publish. This form is published with all life science papers and is intended to promote consistency and transparency in reporting. All life sciences submissions use this form; while some list items might not apply to an individual manuscript, all fields must be completed for clarity.

For further information on the points included in this form, see Reporting Life Sciences Research. For further information on Nature Research policies, including our data availability policy, see Authors & Referees and the Editorial Policy Checklist.

▶ ⊢∨	perimental	ldacian
L	perimental	i ucsigii

	_		
1.	Samp		C176
⊥.	Jailib	ľ	3120

Describe how sample size was determined.

No calculation for sample size was performed. Cohort size was determined using samples that had undergone whole exome sequencing at the time of data freeze.

2. Data exclusions

Describe any data exclusions.

Individuals with either an identified chromosomal aneuploidy or a copy number variation that is known to be associated with CHD were not included.

3. Replication

Describe whether the experimental findings were reliably reproduced.

No replication

4. Randomization

Describe how samples/organisms/participants were allocated into experimental groups.

CHD: Presence of structural congenital heart disease Control: Unaffected sibling or parent of proband with autism; ascertained for absence of autism

5. Blinding

Describe whether the investigators were blinded to group allocation during data collection and/or analysis.

blinding

Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.

6. Statistical parameters

For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or the Methods section if additional space is needed).

n/a	Con	firmed
	\boxtimes	The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
	\boxtimes	A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly.
\boxtimes		A statement indicating how many times each experiment was replicated
	\boxtimes	The statistical test(s) used and whether they are one- or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
	\boxtimes	A description of any assumptions or corrections, such as an adjustment for multiple comparisons
	\boxtimes	The test results (e.g. p values) given as exact values whenever possible and with confidence intervals noted
	\boxtimes	A summary of the descriptive statistics, including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
		Clearly defined error hars

See the web collection on statistics for biologists for further resources and guidance.

Software

Policy information about availability of computer code

7. Software

Describe the software used to analyze the data in this study.

GATK: (https://www.broadinstitute.org/gatk/); TrioDeNovo: (http:// genome.sph.umich.edu/wiki/Triodenovo); DenovolyzeR: (http:// denovolyzer.org); Plink: (http://pngu.mgh.harvard.edu/~purcell/plink); MetaSVM/ANNOVAR: (http://annovar.openbioinformatics.org); NHLBI ESP: (http://evs.gs.washington.edu/EVS/); ExAC03: (http:// exac.broadinstitute.org); R version 3.4.1; Python 2.7 In house pipelines will be provided by the authors on request

For all studies, we encourage code deposition in a community repository (e.g. GitHub). Authors must make computer code available to editors and reviewers upon request. The Nature Methods guidance for providing algorithms and software for publication may be useful for any submission.

Materials and reagents

Policy information about availability of materials

8. Materials availability

Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.

No unique materials

9. Antibodies

Describe the antibodies used and how they were validated for use in No antibodies the system under study (i.e. assay and species).

10. Eukaryotic cell lines

- a. State the source of each eukaryotic cell line used.
- b. Describe the method of cell line authentication used.
- c. Report whether the cell lines were tested for mycoplasma contamination.
- d. If any of the cell lines used in the paper are listed in the database of commonly misidentified cell lines maintained by ICLAC, provide a scientific rationale for their use.

No cell lines

NΑ

NA

Animals and human research participants

Policy information about studies involving animals; when reporting animal research, follow the ARRIVE guidelines

11. Description of research animals

Provide details on animals and/or animal-derived materials used in the study.

No animals used

Policy information about studies involving human research participants

12. Description of human research participants

Describe the covariate-relevant population characteristics of the human research participants.

Population characteristics for case and control groups are provided in Supplementary Figure 1 and Supplementary tables S2, S3a-c